Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients-Reference-Cited by-同舟云学术

Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients

Published:2023-11 Issue: Volume:168 Page:105584
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Schiaroli Elisabetta^ORCID,Gidari Anna,Brachelente Giovanni,Bicchieraro Giulia,Spaccapelo Roberta^ORCID,Bastianelli Sabrina,Pierucci Sara,Busti Chiara,Pallotto Carlo,Malincarne Lisa,Camilloni Barbara^ORCID,Falcinelli Flavio,De Socio Giuseppe Vittorio,Villa Alfredo,Mencacci Antonella,Francisci Daniela

Funder

Fondazione Cassa di Risparmio di Perugia

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference28 articles.

1. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety;Fendler;Nat. Rev. Clin. Oncol.,2022

2. Factors associated with COVID-19-related death using open SAFELY;Williamson;Nature,2020

3. Outcomes of patients with hematologic malignancies and COVID-19. Meta-analysis;Vijenthira;Blood,2020

4. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer;Aydillo;N. Engl. J. Med.,2020

5. Persistence and evolution of SARS-CoV-2 in an immunocompromised host;Choi;N. Engl. J. Med.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response;Vaccines;2024-08-01

2. SARS-CoV-2 Molecular Evolution: A Focus on Omicron Variants in Umbria, Italy;Microorganisms;2024-06-29

3. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?;Viruses;2024-02-25